Shares of Radius Health Inc (NASDAQ:RDUS) dropped 5.2% on Tuesday . The company traded as low as $29.51 and last traded at $29.58. Approximately 1,158,090 shares were traded during mid-day trading, an increase of 19% from the average daily volume of 976,120 shares. The stock had previously closed at $31.19.

Several analysts recently commented on RDUS shares. Cantor Fitzgerald set a $58.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research report on Thursday, December 7th. Jefferies Group cut their price objective on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a research report on Friday, November 3rd. Citigroup started coverage on shares of Radius Health in a research report on Wednesday, December 6th. They set a “neutral” rating and a $30.00 price objective on the stock. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price objective on shares of Radius Health in a research report on Friday, October 6th. Finally, Maxim Group reissued a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $48.00.

The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same quarter last year, the business earned ($1.07) earnings per share. analysts expect that Radius Health Inc will post -5.57 earnings per share for the current year.

In related news, major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were purchased at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the acquisition, the insider now directly owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Brent Hatzis-Schoch purchased 1,778 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were bought at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the acquisition, the vice president now owns 2,278 shares in the company, valued at $63,989.02. The disclosure for this purchase can be found here. Insiders have purchased a total of 317,678 shares of company stock worth $9,975,498 over the last three months. 15.00% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BB Biotech AG boosted its holdings in shares of Radius Health by 11.0% during the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after acquiring an additional 498,400 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Radius Health by 18.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after acquiring an additional 569,300 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Radius Health by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after acquiring an additional 135,071 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Radius Health by 10.0% during the 2nd quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after acquiring an additional 262,896 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Radius Health by 12.9% during the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after acquiring an additional 213,399 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “Radius Health (RDUS) Trading Down 5.2%” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/12/radius-health-rdus-trading-down-5-2.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Receive News & Stock Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related stocks with our FREE daily email newsletter.